Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

Author:

Dhanji Nishit1,Decimoni Tassia Cristina2ORCID,Dyer Matthew T. D.3,May Jessica R.3ORCID,van de Wetering Gijs4,Petersohn Svenja4ORCID,Nickel Katharina5,Silva Amanda6,Muniz David Q. B.7,Casagrande D. Oliveira Ana Paula2

Affiliation:

1. Modeling & Meta-Analysis, OPEN Health, Oxford, UK

2. Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil

3. WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK

4. Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands

5. Modeling & Meta-Analysis, OPEN Health, Berlin, Germany

6. Commercialization Intercon Medical, Medical and Regulatory Affairs, São Paulo, SP, Brazil

7. Hospital Sírio-Libanês, São Paulo, Brazil

Publisher

Informa UK Limited

Subject

Health Policy

Reference48 articles.

1. International Agency for Research on Cancer (IARC). Brazil fact sheets. GLOBOCAN 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf.

2. An estimate of premature deaths averted with immunotherapy in treating Brazilian patients with advanced clear cell renal cell carcinoma. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16114#:∼:text=Background%3A%20Clear%20cell%20renal%20cell in%20metastatic%20RCC%20(mRCC).

3. Brazilian data of renal cell carcinoma in a public university hospital

4. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

5. Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3